ARQT Long Call Strategy

ARQT (Arcutis Biotherapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata.

ARQT (Arcutis Biotherapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.29B, a trailing P/E of 120.28, a beta of 1.53 versus the broader market, a 52-week range of 15.1-31.77, average daily share volume of 1.7M, a public-listing history dating back to 2020, approximately 354 full-time employees. These structural characteristics shape how ARQT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.53 indicates ARQT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 120.28 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a long call on ARQT?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

ARQT snapshot

As of August 14, 2026, spot at $25.92, ATM IV 42.30%, IV rank 10.01%, expected move 12.13%. The long call on ARQT below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long call structure on ARQT specifically: ARQT IV at 42.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a ARQT long call, with a market-implied 1-standard-deviation move of approximately 12.13% (roughly $3.14 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ARQT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ARQT should anchor to the underlying notional of $25.92 per share and to the trader's directional view on ARQT stock.

ARQT long call setup

The ARQT long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ARQT at $25.92 on that close, the first option leg uses a $25.92 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ARQT chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ARQT shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$25.92N/A

ARQT long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

ARQT long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on ARQT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on ARQT

Long calls on ARQT express a bullish thesis with defined risk; traders use them ahead of ARQT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

ARQT thesis for this long call

The market-implied 1-standard-deviation range for ARQT extends from approximately $22.78 on the downside to $29.06 on the upside. A ARQT long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ARQT IV rank near 10.01% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ARQT at 42.30%. As a Healthcare name, ARQT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ARQT-specific events.

ARQT long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ARQT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ARQT alongside the broader basket even when ARQT-specific fundamentals are unchanged. Long-premium structures like a long call on ARQT are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ARQT chain quotes before placing a trade.

Frequently asked questions

What is a long call on ARQT?
A long call on ARQT is the long call strategy applied to ARQT (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ARQT stock at $25.92 on the most recent close, the strikes shown on this page are snapped to the nearest listed ARQT chain strike and the premiums come straight from that session's bid/ask midpoint.
How are ARQT long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ARQT long call priced from the end-of-day chain at a 30-day expiry (ATM IV 42.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ARQT long call?
The breakeven for the ARQT long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ARQT market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.13%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on ARQT?
Long calls on ARQT express a bullish thesis with defined risk; traders use them ahead of ARQT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current ARQT implied volatility affect this long call?
ARQT ATM IV is at 42.30% with IV rank near 10.01%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related ARQT analysis